Mabpharm Limited

As of December 31, 2025, Mabpharm Limited carries a market capitalization of 2.06B, placing it among publicly traded companies globally. Its enterprise value stands at 2.30B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Mabpharm Limited's next confirmed earnings release is scheduled for March 31, 2027.

As of December 31, 2025, Mabpharm Limited has 4.12B shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Mabpharm Limited maintains a current ratio of 0.81, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Mabpharm Limited's stock has declined approximately 29.03% over the past 52 weeks. The 50-day moving average sits at 0.43, while the 200-day moving average is 0.49.

As of December 31, 2025, Mabpharm Limited holds 121.59M in cash and equivalents against 363.62M in total debt, resulting in a net debt position of 186.04M. Total book value stands at 175.06M, with working capital of -111.00M providing operational flexibility.